Skip to main content
Clinical Trials/PACTR202001481782473
PACTR202001481782473
Completed
Phase 3

Quality of life among Children on Dialysis and effect of Omega 3 Fatty Acid Supplementation

Mohamed Samir0 sites31 target enrollmentJanuary 18, 2020

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Nutritional, Metabolic, Endocrine
Sponsor
Mohamed Samir
Enrollment
31
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Children with End Stage Renal Disease (ESRD) are liable to have poor quality of life. This work aimed to assess quality of life and study the effect of omega-3 fatty acid (?-3 FA) supplementation among children on dialysis. A pilot study was conducted on 31 hemodialysis children and an equal number of matched controls. Nonpharmacological treatments include dietary supplementation with ?-3 FA had been given to the patients for 16 weeks. PedsQL Measurement Model to measure quality of life (QOL) and laboratory investigations to assess the condition had been carried out. Patients had poorer QOL in comparison with controls especially regarding health activities (P<0.001). Poor QOL was reported among females and ages <12y (P<0.05). After ?-3 FA supplementation, the scores get improved not to the degree of controls scores but it showed some improvement (P<0.05). Lipid profile, inflammatory markers and efficiency of dialysis showed improvement (P<0.05). QOL among children on dialysis is affected by the disease. Beneficial effects of ?-3 FA were detected in children on dialysis reflected on improved quality of life. Further application on large sample to allow routine use for those patients is needed.

Registry
who.int
Start Date
January 18, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Mohamed Samir

Eligibility Criteria

Inclusion Criteria

  • Children with ESRD with
  • \- A glomerular filtration rate of less than 10 ml/min/1\.73 m2
  • \- Age less than 14 years, and
  • \- Regular hemodialysis at least three sessions per week for at least 3 months before the study will be included in the study.

Exclusion Criteria

  • Patients with
  • \- Pre\-dialysis stages of CKD,
  • \- On chronic peritoneal dialysis,
  • \- Regular hemodialysis \< 3 months,
  • \- Primary (non\-uremic) cardiovascular disease will be excluded from the study.
  • Forty nine patients were enrolled, 31 patients (17 males and 14 females, aged from 8\-14 years) fit the inclusion criteria while 18 patients were excluded (due to exclusion criteria, acute infection, hospitalization, febrile illness and non\-compliance).

Outcomes

Primary Outcomes

Not specified

Similar Trials